Loading...
•
Sep 30, 2022
Coherus Q3 2022 Earnings Report
Coherus reported a net revenue of $45.4 million, driven by UDENYCA sales, and launched CIMERLI™ in the United States.
Key Takeaways
Coherus BioSciences reported third quarter 2022 financial results, with UDENYCA® net sales of $45.4 million. CIMERLI™ was launched in the United States on October 3rd. The company is planning for 2023 commercial launches of toripalimab, YUSIMRY™ and UDENYCA® OBI. They are targeting a return to profitability in 2024.
UDENYCA® net sales reached $45.4 million in Q3 2022.
CIMERLI™ was launched in the United States on October 3rd.
Planning is underway for 2023 commercial launches of toripalimab, YUSIMRY™ and UDENYCA® OBI.
The company is targeting a return to profitability in 2024.
Forward Guidance
Coherus is revising the guidance range of combined 2022 R&D and SG&A expenses from $375 - $395 million to a range of $375 - $385 million. This guidance includes $55 million to $60 million of stock-based compensation expense and excludes the $35 million license fee paid in the first quarter of 2022 for CHS-006 as well as a potential $25 million milestone payable upon FDA approval of the toripalimab BLA for nasopharyngeal carcinoma.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...